← Eichor
Study identifier: NCT07216690 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Pregnenolone as a Treatment for Cannabis Intoxication

Condition: Cannabis Intoxication  ·  Sponsor: Johns Hopkins University

PhasePhase 2
Planned participants20
Who can joinAll sexes, 18 Years to 65 Years
Healthy volunteersYes

About this study

The present study will characterize the ability of pregnenolone to reverse the acute intoxication and associated symptoms of cannabis. Healthy adults with a history of cannabis use will be recruited to participate in a placebo-controlled, within-subject crossover study at Johns Hopkins Behavioral Pharmacology Research Unit (BPRU). By clarifying the ability of pregnenolone to reverse cannabis intoxication symptoms, this study will pave the way for larger clinical studies that provide a foundation for the development of future CB1-receptor NAM medications that could be applied in emergency situations and potentially validate pregnenolone as a treatment for cannabis intoxication.

This description comes directly from the study's public registry record.

Talk to the study team

David Wolinsky, MD  ·  (646) 572-6959  ·  dwolins2@jhmi.edu

Always discuss trial participation with your own doctor first.

Locations (1)

Johns Hopkins University School of Medicine, Behavioral Pharmacology Research UnitBaltimore, Maryland, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07216690